TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Sugar recovery in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Atezolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Phase 2 Dose (RP2D) of Atezolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of the condition
Endpoint domain: Mortality/survival
Primary endpoint: Central-line associated bloodstream infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Primary bloodstream infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Catheter colonization rate
Endpoint domain: Adverse events/effects
Primary endpoint: Visual Scale Pain VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spinal fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Bother Score (BS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Work Rehabilitation Questionnaire (WORQ)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Speech intelligibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in simulated field hockey match demands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in repeated-sprint-ability test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of colonies that grew
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Effective Volume of Ropivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Scalp hair cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Active knee extension range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage time frozen (%TF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mammography receipt
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Renal blood oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in dental plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vascular calcification score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Detection of peptide and protein markers in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarker Ki67 Associated With Progression to Invasive Breast Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of Luminal Progenitor Epithelial Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sphere Formation Efficiency of Mammary Stem Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total Dose of Propofol Administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of auditory hallucinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of HIV, HBV or HCV positive patients identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of tuberculosis patients identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Overall efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of admissions of patients with AF
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: VFS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal beta-amyloid detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Patients With Fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of new diffusion weighted abnormalities post-procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: metabolome of symptomatic uncomplicated Diverticular Disease (SUDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: changes in the intestinal microbiota following treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative incidence of neutrophil and platelets engraftment at day +30 after HSCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: cumulative incidence of transplant-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: TSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety issues
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic accuracy of resonance magnetic imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with clinically significant changes in 12-lead ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sustained Virological Response at 24 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sustained Virological Response at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Composite serious adverse cardiac events and stroke
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline cardiorespiratory fitness at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline muscle strength at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Decrease in Vitiligo Area Scoring Index (VASI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Chloroprocaine Plasma Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of Intestinal Polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Erectile function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Morphine Equivalents at 72 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: puncture time of subclavian vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of Patients With Dose Limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Peak Expiratory Flow (PEF) 5 Minutes After Morning Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Subjects With Anti-HBs Antibody Concentrations Above Cut-off Value (ELISA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Anti-HBs Antibody Concentrations Above Cut-off Value (CLIA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area Under the Concentration-Time Curve From Zero to 24 Hours After Dosing (AUC0-24) of R-Methadone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma Concentration at 24 Hours After Dosing (C24) of R-Methadone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of R-Methadone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients completing the study treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: pulmonary pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnostic concordance in detection of cerebral meningiomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Trough Forced Expiratory Volume in one second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction ratios of lambda immunoglobulin free light chains (λ-FLC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction ratios of kappa immunoglobulin free light chains (k-FLC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction ratios of chitinase-3-like protein 1 (YKL-40)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction ratios of fibroblast growth factor 23 (FGF-23)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction ratios of serum beta-2 microglobulin (β2M)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Pain Scores at 48hrs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Intragraft Thrombus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Previously Untreated DLBCL Participants With Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With CR Defined by PET/CT Scan in DE-DLBCL Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants Who Had Positive Genetic Test Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Safety Events
Endpoint domain: Adverse events/effects
Primary endpoint: Protein excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rod-mediated dark adaptation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incident age-related macular degeneration (AMD) or progression of AMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Deficit in critical components of personal identity
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Visual acuity test with Early Treatment Diabetic Retinopathy Study (ETDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Daily living task dependent on vision (DLTV)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Abnormal Laboratory Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Changes From Baseline in Vital Signs Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of successful airway device insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Frequency and types of serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Correlation and agreement with PaCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With at Least One Adverse Event (AE) Leading to Hospitalization or Death
Endpoint domain: Adverse events/effects
Primary endpoint: Coefficient of Variation of Rad-67
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: walking performance (walking time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: walking performance (treadmill walking speed)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: walking performance (number of stepping)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Decline in Forced Vital Capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Response of Overall IBS Symptom Relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Faces Pain Scale-Revised (FPS-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term effects of HCV clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-t) of Benapenem
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in SNOT-22 scores from Baseline
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in serum concentration of IL-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in concentration of serum TGF-beta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in concentration of serum IFN-gamma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean headache rating change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIH priority score
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Executive Function Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: tumor penetration of EC1456
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pain on a visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Efficiency
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Functional Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: clinically significant periprocedural adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Requesting Pain Medication
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of women with back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of women with stress urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Occurrence of regimen related toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Event-free Survival Rate at 1 Year
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Invasive fungal infections
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of total RF application until bidirectional conduction block is achieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Management of anaphylaxis episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnostic utility (sensitivity/specificity) of fast MR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medical resource utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Modified surgical rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Sitting Clinic Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incomplete resection rates in polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Barriers towards exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Walk capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade of oral mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Methylation status of GSTP1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Histopathology of prostate fossa biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants Experiencing Grade 3 and 4 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Prostate-specific Antigen (PSA) Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in PSA Slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: albuminuria as measured by ACR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Hands pigmentation change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Variation of apparent diffusion coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Who Met the ACR20 Criteria at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Who Had a DAS28 [ESR] ≤ 3.2 at Week 104
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction and breast-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cervical length measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Incidence of overall anastomotic leak
Endpoint domain: Adverse events/effects
Primary endpoint: Median Percent Change From Baseline in Average Walking Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of lymph nodes showing metastatic cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time taken for alleviation of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gingival color change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac flow variation at 0 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac flow variation at 6 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Weight SDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation Dose (mSv)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rebound pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Addenbrooke's Cognitive Examination III (ACE-III)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Patient Dignity Inventory (PDI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Soy-specific IgE antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Highest level of pain during the incision and drainage of the abscess
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute Hemodynamic Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acute Respiratory Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decision satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Nerve Excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in HCV ribonucleic acid (RNA) level from Baseline to Day 15
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants experiencing adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Sokolow-Lyon index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cornell index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pain during the root canal treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Caregiver Burden and Stress
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change in Caregiver Coping Skills
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Caregiver Level of Satisfaction With Social Support
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Virological Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of percutaneous closure procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity and specificity in differentiating cancer/normal tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intestinal microbiota co-re-emergence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentrations of Cytokines and Chemokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of spontaneous ureteral stone expulsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Epileptic seizure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Catheters Visualized That Reached Intended Target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Adherence to self-monitoring
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attaining the goal of dietary time restriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes